Farxiga Patent Protection
17 patents · AstraZeneca AB
Patent Details
| Patent # | Title | Assignee | Expires | Status |
|---|---|---|---|---|
| 6515117 | Drug substance & product patent (incl. pediatric exclusivity extension) | AstraZeneca AB | Apr 4, 2026 | Expired |
| 8906851 | Orange Book listed patent (incl. pediatric exclusivity extension) | AstraZeneca AB | Feb 18, 2027 | 0.7y left |
| 8329648 | Orange Book listed patent (incl. pediatric exclusivity extension) | AstraZeneca AB | Feb 18, 2027 | 0.7y left |
| 8501698 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | AstraZeneca AB | Dec 20, 2027 | 1.5y left |
| 8361972 | Orange Book listed patent (incl. pediatric exclusivity extension) | AstraZeneca AB | Sep 21, 2028 | 2.2y left |
| 8221786 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | AstraZeneca AB | Sep 21, 2028 | 2.2y left |
| 8716251 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | AstraZeneca AB | Sep 21, 2028 | 2.2y left |
| 7851502 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | AstraZeneca AB | Feb 19, 2029 | 2.7y left |
| 7919598 | Drug substance (composition of matter) patent (incl. pediatric exclusivity extension) | AstraZeneca AB | Jun 16, 2030 | 4.0y left |
| 8721615 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | AstraZeneca AB | Jul 18, 2030 | 4.1y left |
| 8685934 | Orange Book listed patent (incl. pediatric exclusivity extension) | AstraZeneca AB | Nov 26, 2030 | 4.4y left |
| 12472194 | Orange Book listed patent (incl. pediatric exclusivity extension) | AstraZeneca AB | Jan 18, 2040 | 13.6y left |
| 11826376 | Orange Book listed patent (incl. pediatric exclusivity extension) | AstraZeneca AB | Jan 18, 2040 | 13.6y left |
| 10973836 | Orange Book listed patent (incl. pediatric exclusivity extension) | AstraZeneca AB | Sep 9, 2040 | 14.2y left |
| 11903955 | Orange Book listed patent (incl. pediatric exclusivity extension) | AstraZeneca AB | Sep 9, 2040 | 14.2y left |
| 12213988 | Orange Book listed patent (incl. pediatric exclusivity extension) | AstraZeneca AB | Oct 1, 2041 | 15.3y left |
| 12409186 | Orange Book listed patent (incl. pediatric exclusivity extension) | AstraZeneca AB | Oct 1, 2041 | 15.3y left |
Related Drug Patent Expirations
12 patents · earliest expires 2027 · AstraZeneca AB
5 patents · earliest expires 2032 · AstraZeneca AB
33 patents · earliest expires 2026 · Novo Nordisk A/S
17 patents · earliest expires 2026 · Novo Nordisk A/S
7 patents · earliest expires 2026 · Astellas Pharma Inc.
2 patents · earliest expires 2027 · Bristol-Myers Squibb Company
Farxiga is one of the data points covered by this site’s U.S. pharmaceutical patent expirations dataset. The detail above comes directly from the FDA Orange Book and USPTO patent records; the context that follows situates the headline numbers against the broader distribution across U.S. brand-name drugs.
Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for Farxiga is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.